Brought to you by 
Takeda and Roivant launch Myovant; Takeda grants rights
07 Jun 2017
Executive Summary
Takeda Pharmaceutical Co. Ltd. and Roivant Sciences Ltd. together launched Myovant Sciences Ltd., a new biotech operating as a Roivant subsidiary that will be focused on therapies for women's health conditions and prostate cancer.
Deal Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
- Specialty Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com